In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery

Basit Öğe Kaydı
dc.authoridARISOY, SEMA/0000-0003-2798-1884
dc.authoridARISOY, SEMA/0000-0003-2798-1884
dc.authoridPEHLIVANOGLU, BILGE/0000-0001-5969-5108
dc.authoridAtalay, Ozbeyen/0000-0002-6183-1460
dc.authoridOnal, Deniz/0000-0002-9604-4539
dc.authorwosidARISOY, SEMA/ABI-2760-2020
dc.authorwosidARISOY, SEMA/V-1458-2017
dc.authorwosidÖNAL, Deniz/JWO-2804-2024
dc.authorwosidPEHLIVANOGLU, BILGE/I-8292-2013
dc.contributor.authorArisoy, Sema
dc.contributor.authorSayiner, Ozgun
dc.contributor.authorComoglu, Tansel
dc.contributor.authorOnal, Deniz
dc.contributor.authorAtalay, Ozbeyen
dc.contributor.authorPehlivanoglu, Bilge
dc.date.accessioned2024-08-04T20:47:13Z
dc.date.available2024-08-04T20:47:13Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractParkinson's disease (PD) is a neurodegenerative disease which is characterized by the loss of dopaminergic neurons in the brain. Levodopa is the drug of choice in the treatment of PD but it exhibits low oral bioavailability (30%) and very low brain uptake due to its extensive metabolism by aromatic amino acid decarboxylase in the peripheral circulation. Moreover, levodopa has psychic, gastrointestinal, and cardiovascular side effects, and most importantly, short and frequent stimulation of dopamine receptors lead to undesirable conditions such as dyskinesia over time. The challenges are to increase the therapeutic efficiency, the bioavailability and decreasing the unfavourable side effects of levodopa. Biocompatible nano-sized drug carriers could address these challenges at molecular level. For this purpose, levodopa-loaded Poly (lactide-co-glycolide) acid nanoparticles were prepared by double emulsion-solvent evaporation method for nose to brain drug delivery. Parameters such as homogenization speed, and external and internal phase content were modified to reach the highest loading efficiency. F1-1 coded formulation showed prolonged release up to 9 h. Carbodiimide method was used for surface modification studies of nanoparticles. The efficacy of the selected nanoparticle formulation has been demonstrated by in vivo experiments in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced PD model in mice.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK) [116S639]en_US
dc.description.sponsorshipThis study is granted by The Scientific and Technological Research Council of Turkey (TUBITAK) with the project no: 116S639.en_US
dc.identifier.doi10.1080/10837450.2020.1740257
dc.identifier.endpage747en_US
dc.identifier.issn1083-7450
dc.identifier.issn1097-9867
dc.identifier.issue6en_US
dc.identifier.pmid32141798en_US
dc.identifier.scopus2-s2.0-85082179525en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage735en_US
dc.identifier.urihttps://doi.org/10.1080/10837450.2020.1740257
dc.identifier.urihttps://hdl.handle.net/11616/99229
dc.identifier.volume25en_US
dc.identifier.wosWOS:000520582000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofPharmaceutical Development and Technologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNasal drug deliveryen_US
dc.subjectlevodopa nanoparticlesen_US
dc.subjectPLGAen_US
dc.subjectParkinson diseaseen_US
dc.subjectwheat germ aglutinine conjugationen_US
dc.subjectin vivo Parkinson disease modelen_US
dc.titleIn vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain deliveryen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu